सभी अध्ययन
भर्तीचरण4हस्तक्षेपात्मक

Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients

This research trial, called TripleTRE, is looking at the best way to start treatment for people with a condition called pulmonary arterial hypertension (PAH), which causes high blood pressure in the lungs. It compares two different treatment approaches for adult patients who are newly diagnosed or haven't been treated for PAH before. One group receives a combination of three medicines: two oral tablets and one medicine (treprostinil) given by injection. The other group receives two oral tablets, which is a common starting treatment. The main goal is to see which treatment helps more patients achieve a 'low risk' status, meaning their condition is better managed. This study will help doctors improve care for PAH patients.

एक नजर में

स्थिति
भर्ती
चरण
चरण4
प्रायोजक
AOP Orphan Pharmaceuticals AG
नामांकन लक्ष्य
110
प्रारंभ
06 Dec 2023
अनुमानित पूर्णता
30 जून 2027

यह अध्ययन किस बारे में है?

Pulmonary arterial hypertension, or PAH, is a serious condition where the blood pressure in the arteries leading to your lungs becomes too high. This makes your heart work much harder and can lead to serious health problems. Doctors are always looking for the best ways to treat PAH and help patients live better lives. This study, called TripleTRE, is exploring whether starting treatment with a combination of three medicines might be more effective than starting with two for certain patients.

Currently, many patients with PAH start treatment with two oral medicines. These medicines work in different ways to relax blood vessels in the lungs and lower blood pressure. TripleTRE is investigating whether adding a third medicine, treprostinil (which is given by injection), right from the start can lead to better outcomes, especially for patients with a higher risk level or more severe symptoms.

This trial is for adults with specific types of PAH who are newly diagnosed or haven't received PAH treatment in the past three months. Researchers will carefully monitor how patients respond to their assigned treatment over several months to understand the safety and effectiveness of each approach. The results could help doctors decide the best way to begin treatment for future PAH patients.

मुख्य निष्कर्ष

  • Compares two starting treatments for PAH: two pills vs. two pills plus an injected medicine.
  • Aims to find out which approach leads to better health for PAH patients.
  • Involves adults (18-70) with specific types of newly diagnosed or untreated PAH.
  • Participation lasts between 6 months and a year with regular hospital visits.
  • You will know which treatment you are receiving (it's 'open-label').

कौन पात्र हो सकता है?

This study is looking for adults aged between 18 and 70 years old who have just been diagnosed with certain types of pulmonary arterial hypertension (PAH) or haven't been treated for it in the last three months. These types include PAH that doesn't have a clear cause (idiopathic), PAH that runs in families (hereditary), PAH caused by medicines or toxins, PAH linked to connective tissue diseases, or PAH with a repaired heart defect from birth.

You might be able to join if your PAH is considered 'intermediate-high risk' or 'intermediate-low risk' but with some severe signs of how your heart and lungs are working. Doctors will do some tests, including a special heart catheterisation, to check your heart and lung pressures and confirm your diagnosis.

However, you won't be able to join if you have certain other types of PAH (like those linked to schistosomiasis, HIV, liver problems, or a widespread skin condition called diffuse systemic sclerosis) or if your heart defect from birth hasn't been fixed. You also can't participate if you've already had PAH-specific treatment recently, if your PAH responds to certain tablets called calcium channel blockers, or if you have certain other lung or heart conditions.

क्या यह अध्ययन आपके लिए उपयुक्त हो सकता है?

यह देखने के लिए इन त्वरित प्रश्नों का उत्तर दें कि क्या आप पात्र हो सकते हैं। यह केवल एक मार्गदर्शिका है — अंतिम निर्णय शोध टीम द्वारा लिया जाता है।.

  1. क्या आपकी उम्र 18 से 70 वर्ष के बीच है?
  2. Have you been diagnosed with PAH recently, or have you not taken PAH medicines in the last 3 months?
  3. Is your PAH one of these types: idiopathic, hereditary, drug/toxin-induced, associated with connective tissue disease, or with corrected congenital heart disease?
  4. Are you able to use reliable contraception if you're a woman who could become pregnant?
अपने परिणाम देखने के लिए हर प्रश्न का उत्तर दें।.

भागीदारी में क्या शामिल है?

If you decide to take part in the TripleTRE study, you'll be randomly assigned to one of two treatment groups, like flipping a coin. You'll receive either two oral medications or the same two oral medications along with treprostinil, which is given by an injection. All medicines will be started within three weeks of joining the study. You'll have regular visits to the hospital for check-ups, tests, and to monitor how you're feeling and how the treatment is working. This will include blood tests, heart and lung function tests, and possibly repeats of the heart catheterisation. The study will follow your progress for about 24 to 48 weeks, which is roughly between six months and a year.

संभावित जोखिम और लाभ

Participating in a study like TripleTRE means you'll receive close medical attention and access to potentially effective treatments for your PAH. While the goal is to find better treatments, there's no guarantee that the treatment you receive will improve your condition, and side effects are possible with any medication. The additional treprostinil in one group is given by injection, which has its own potential risks like injection site reactions. The research team will explain all known risks of the medicines used. You have the right to leave the study at any time, for any reason, without it affecting your usual medical care.

स्थान (19)

  • Ordensklinikum Linz
    सत्यापित पोस्टकोड
    लिंज़, ऑस्ट्रिया· भर्ती
  • Medical University Vienna
    सत्यापित पोस्टकोड
    वियना, ऑस्ट्रिया· भर्ती
  • Fakultní Nemocnice Olomouc
    सत्यापित पोस्टकोड
    Olomouc, Czechia· अभी भर्ती नहीं हो रही है
  • Všeobecná fakultní nemocnice v Praze
    सत्यापित पोस्टकोड
    प्राग, चेकिया· अभी भर्ती नहीं हो रही है
  • Hôpital Bicêtre-- Assistance Publique Hopitaux de Paris
    सत्यापित पोस्टकोड
    पेरिस, फ्रांस· अभी भर्ती नहीं हो रही है
  • Hôpitaux Universitaires de Strasbourg
    सत्यापित पोस्टकोड
    स्ट्रासबर्ग, फ्रांस· अभी भर्ती नहीं हो रही है
  • DRK Kliniken Berlin Westend
    सत्यापित पोस्टकोड
    बर्लिन, जर्मनी· अभी भर्ती नहीं हो रही है
  • University Hospital Carl Gustav Carus of Technical University Dresden
    सत्यापित पोस्टकोड
    ड्रेसडेन, जर्मनी· अभी भर्ती नहीं हो रही है
  • Universitätsmedizin Greifswald
    सत्यापित पोस्टकोड
    Greifswald, Germany· अभी भर्ती नहीं हो रही है
  • Gottsegen National Cardiovascular lnstitute
    सत्यापित पोस्टकोड
    बुडापेस्ट, हंगरी· अभी भर्ती नहीं हो रही है
  • Medical University of Szeged
    सत्यापित पोस्टकोड
    Szeged, Hungary· अभी भर्ती नहीं हो रही है
  • Sapienza University of Rome
    सत्यापित पोस्टकोड
    Rome, Italy· भर्ती

सामान्य प्रश्न

What is PAH?

PAH stands for pulmonary arterial hypertension. It's a condition where the blood pressure in the arteries that carry blood from your heart to your lungs is too high, making your heart work harder.

किस प्रकार की दवाओं का परीक्षण किया जा रहा है?

The study is testing combinations of medicines. Both groups will get two oral medicines. One group will also get an additional medicine called treprostinil, which is given by injection.

मेरे लिए अध्ययन कितने समय तक चलेगा?

If you join the study, your treatment and monitoring will last for approximately 6 to 12 months (24 to 48 weeks).

क्या मुझे पता चलेगा कि मुझे कौन सा उपचार मिल रहा है?

Yes, this is an 'open-label' study, which means both you and your doctor will know whether you are receiving the two oral medicines or the three-medicine combination.

क्या मुझे अध्ययन में शामिल होने के लिए भुगतान करना होगा?

No, all study-related treatments and tests are provided at no cost to you.

और अधिक जानने के लिए कैसे पता करें

Clinical Project Manager

किसी अध्ययन में भाग लेने का निर्णय लेने से पहले हमेशा अपने जीपी या विशेषज्ञ से बात करें।.

भाग लेने में रुचि रखते हैं?

अपनी रुचि दर्ज करें

अपने विवरण साझा करें और अनुसंधान टीम के लिए "Initial Triple Therapy Including Parenteral Treprostinil vs …यदि आप पात्र हो सकते हैं तो आपसे संपर्क करेंगे। भाग लेने के लिए सहमति देने से पहले हमेशा अपने जीपी से बात करें।.

चर्चा

समुदाय चर्चा

हमारे फोरम द्वारा संचालित community.patient.info. कृपया सम्मानजनक रहें — यह चिकित्सा सलाह नहीं है।.